诺和诺德司美格鲁肽注射液慢性肾脏病适应症在华获批

Core Viewpoint - Novo Nordisk announced that the National Medical Products Administration (NMPA) has officially approved the new indication for semaglutide injection (Nuohe Tai) for chronic kidney disease (CKD), making it the first and only GLP-1 receptor agonist (GLP-1RA) approved in China to reduce the risk of eGFR decline, end-stage kidney disease, and cardiovascular death in adult patients with type 2 diabetes and CKD [1] Group 1 - The approval marks a significant milestone for Novo Nordisk in the Chinese market, expanding the therapeutic options available for patients with type 2 diabetes and CKD [1] - Semaglutide is positioned to address a critical need in managing the complications associated with chronic kidney disease in diabetic patients [1] - This development may enhance Novo Nordisk's competitive edge in the diabetes and CKD treatment landscape in China [1]